Regulatory T cell

The regulatory T cells (Tregs /ˈtrɛɡ/ or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.[1] Treg cells express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4+ cells.[2] Because effector T cells also express CD4 and CD25, Treg cells are very difficult to effectively discern from effector CD4+, making them difficult to study. Research has found that the cytokine transforming growth factor beta (TGF-β) is essential for Treg cells to differentiate from naïve CD4+ cells and is important in maintaining Treg cell homeostasis.[3]

Mouse models have suggested that modulation of Treg cells can treat autoimmune disease and cancer and can facilitate organ transplantation[4] and wound healing.[5] Their implications for cancer are complicated. Treg cells tend to be upregulated in individuals with cancer, and they seem to be recruited to the site of many tumors. Studies in both humans and animal models have implicated that high numbers of Treg cells in the tumor microenvironment is indicative of a poor prognosis, and Treg cells are thought to suppress tumor immunity, thus hindering the body's innate ability to control the growth of cancerous cells.[6] Immunotherapy research is studying how regulation of T cells could possibly be utilized in the treatment of cancer.[7]

  1. ^ Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. (May 2006). "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells". Nature. 441 (7090): 235–238. Bibcode:2006Natur.441..235B. doi:10.1038/nature04753. PMID 16648838. S2CID 4391497.
  2. ^ Curiel TJ (May 2007). "Tregs and rethinking cancer immunotherapy". The Journal of Clinical Investigation. 117 (5): 1167–1174. doi:10.1172/JCI31202. PMC 1857250. PMID 17476346.
  3. ^ Chen W (August 2011). "Tregs in immunotherapy: opportunities and challenges". Immunotherapy. 3 (8): 911–914. doi:10.2217/imt.11.79. PMID 21843075.
  4. ^ Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z (October 2011). "Human FoxP3+ regulatory T cells in systemic autoimmune diseases". Autoimmunity Reviews. 10 (12): 744–755. doi:10.1016/j.autrev.2011.05.004. PMID 21621000.
  5. ^ Nosbaum A, Prevel N, Truong HA, Mehta P, Ettinger M, Scharschmidt TC, et al. (March 2016). "Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing". Journal of Immunology. 196 (5): 2010–2014. doi:10.4049/jimmunol.1502139. PMC 4761457. PMID 26826250.
  6. ^ Adeegbe DO, Nishikawa H (2013). "Natural and induced T regulatory cells in cancer". Frontiers in Immunology. 4: 190. doi:10.3389/fimmu.2013.00190. PMC 3708155. PMID 23874336.
  7. ^ Curiel TJ (April 2008). "Regulatory T cells and treatment of cancer". Current Opinion in Immunology. 20 (2): 241–246. doi:10.1016/j.coi.2008.04.008. PMC 3319305. PMID 18508251.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search